Tools   Select Another Resource Report Type

http://acsr.ucsf.edu/

A biorepository for HIV-infected human biospecimens from a wide spectrum of HIV-related or associated diseases, including cancer, and from appropriate HIV-negative controls. The ACSR has formalin-fixed paraffin embedded biospecimens, fresh frozen biospecimens, malignant cell suspensions, fine needle aspirates, and cell lines from patients with HIV-related malignancies. It also contains serum, plasma, urine, bone marrow, cervical and anal specimens, saliva, semen, and multi-site autopsy speicmens from patients with HIV-related malignancies including those who have participated in clinical trials. The ACSR has an associated databank that contains prognostic, staging, outcome and treatment data on patients from whom tissues were obtained. The ACSR database contains more than 300,000 individual biospecimens with associated clinical information. Biospecimens are entered into the ACSR database by processing type, disease category, and number of cases defined by disease category.

Proper citation: AIDS and Cancer Specimen Resource (RRID:SCR_004216) Copy   

•   Source: SciCrunch Registry

http://www.dnaz.org/Home.aspx

Donor Network of Arizona is the federally designated, not-for-profit, organ procurement organization for the state of Arizona and a tissue and eye recovery organization. DNA serves five organ transplant centers in Arizona with the combined capacity to perform heart, lung, kidney, pancreas and liver transplants. * Our Mission: We make the most of life through the gift of organ and tissue donation. * Our Vision: We challenge ourselves and others everyday to realize Arizona''s potential to save and improve lives. DNA shares organs regionally and nationally through the United Network for Organ Sharing''s (UNOS) national network. DNA is accredited by the Association of Organ Procurement Organization, American Association of Tissue Banks and the Eye Bank Association of America.

Proper citation: Donor Network of Arizona (RRID:SCR_004330) Copy   

•   Source: SciCrunch Registry

http://www.walescancerbank.com/

The Wales Cancer Bank aims to collect samples of tumour, normal tissue and blood from all patients in Wales who are undergoing an operation to remove tissue where cancer is a possible diagnosis. These samples will be banked to build up a research resource that will be used by research groups to help understand the molecular mechanisms involved in cancer and work towards the selection of optimum targeted treatment for individuals. The Wales Cancer Bank is licensed by the Human Tissue Authority (license 12107) to store human tissue for research and has ethics approval from the Wales Multicentre Research Ethics Committee to collect and issue samples for cancer related research.

Proper citation: Wales Cancer Bank (RRID:SCR_004331) Copy   

•   Source: SciCrunch Registry

http://www.m2gen.com/pages/biorepository.cfm

THIS RESOURCE IS NO LONGER IN SERVCE, documented September 2, 2016. The M2Gen Biorepository offers the world's largest cancer-focused tissue biobank linked to longitudinal clinical and molecular data. We provide well-annotated, high quality tissue and clinical data to support research and clinical partnerships. M2Gen's Biorepository team includes dedicated pathologists, biobanking specialists and licensed laboratory staff. Quality control assessment is performed by board-certified pathologists.

Proper citation: M2Gen Biorepository (RRID:SCR_004332) Copy   

•   Source: SciCrunch Registry

http://www.ovcare.ca/research/gynaecologic_tissue_bank/

The OvCaRe Tissue Bank is housed within the Vancouver General Hospital Department of Pathology and the British Columbia Cancer Agency. This bank contains tumour samples from over 1100 patients. The tissue samples in the bank are collected from consenting patients within 30 minutes of surgical excision and stored in a variety of forms, including snap frozen, formalin fixed, and as live cells. As of 2007, serum, plasma, and buffy coat are also being collected for every case within the tissue bank. In addition to providing research material for OvCaRe researchers, the OvCaRe Tumour Bank is more active than any other tumour bank in sending samples to research collaborators and has already contributed to 43 national and international research projects. This and other tissue banks provide the foundation for translational research in medicine. In order for these samples to be used by current technologies such as Illumina whole transcriptome sequencing, the samples must be of extremely high quality. We have currently sent a selection of our samples to The Cancer Genome Atlas Project for analysis and were told by researchers there that our samples were among the best quality that they had encountered around the world. Serum Bank The OvCaRe serum bank is located at the British Columbia Cancer Agency. This bank contains over 10,000 serum samples that have been submitted for CA-125 testing as well as samples collected from patients who have consented to have their tumours submitted to the OvCaRe Tumour Bank. Like the tumour bank, these resources are available to collaborating researchers. Ovarian Cancer Tissue Microarrays The ovarian cancer tissue microarray facility from all available early ovarian cancer cases in the province for the period 1984-2000 (541 samples) was created by Dr. Blake Gilks and is the largest tissue microarray of early ovarian cancer samples. This population based series was generated in the Genetic Pathology Evaluation Center (GPEC), a laboratory supported by a Michael Smith Foundation for Health Research Unit Grant and is being used by over 20 different local and international collaborative studies. Two other ovarian cancer tissue microarrays are also built and are available to interested collaborators. All samples in the tissue microarray are linked to clinical outcomes at the Cheryl Brown Ovarian Cancer Outcomes Unit.

Proper citation: British Columbia Gynaecologic Tissue Bank (RRID:SCR_004171) Copy   

•   Source: SciCrunch Registry

http://www.inmex.ca./INMEX/

A web-based tool to support meta-analysis of multiple gene-expression data sets, as well as to enable integration of data sets from gene expression and metabolomics experiments. INMEX contains three functional modules. The data preparation module supports flexible data processing, annotation and visualization of individual data sets. The statistical analysis module allows researchers to combine multiple data sets based on P-values, effect sizes, rank orders and other features. The significant genes can be examined in functional analysis module for enriched Gene Ontology terms or Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, or expression profile visualization. INMEX has built-in support for common gene/metabolite identifiers (IDs), as well as 45 popular microarray platforms for human, mouse and rat. Complex operations are performed through a user-friendly web interface in a step-by-step manner.

Proper citation: INMEX (RRID:SCR_004173) Copy   

•   Source: SciCrunch Registry

http://www.mts-stl.org/

For 35 years, Mid-America Transplant Services (MTS) has served as the regional organ and tissue procurement organization for eastern Missouri, southern Illinois, and northeast Arkansas, serving 4.3 million people in 84 counties. From our founding goal to assist in the coordination of kidney donations, we have grown to become a multi-faceted organization dedicated to saving lives and enhancing the quality of all donated organs and tissues currently available for transplant. MTS''s primary service offering is to facilitate and coordinate the organ and tissue donation process. With a mission to save lives through excellence in organ and tissue donation, we have been at the forefront of enhancing the quality of organs and tissue for transplant. Throughout our history, we have relentlessly pursued our core values of compassion, quality, teamwork, and honesty to create a positive donation experience for Donor Families, which is at the heart of what matters most to MTS. Located in Saint Louis, Missouri, MTS is one of 58 federally designated organizations of its kind in the United States. Incorporated in the State of Missouri, MTS is a private, not-for-profit 501(c)(3). To fulfill our mission, we work closely with the four transplant centers and over 110 donor hospitals located within our service area.

Proper citation: Mid-America Transplant Services (RRID:SCR_004400) Copy   

•   Source: SciCrunch Registry

http://www.cancer.duke.edu/modules/TissueProcurement29/index.php?id=1

THIS RESOURCE IS NO LONGER IN SERVICE, documented on July 16, 2013. Over 10,000 patient consents, 5,000 banking events, and 40,000 biospecimens have been processed to date with storage of both formalin fixed paraffin embedded (FFPE) tissue and frozen tissue located within multiple freezers spanning temperatures in the range of -80 degrees to -180 degrees C depending on protocol requirements. Considerable effort continues to be expended to assure compliance with IRB, NIH and HIPAA best practices and guidelines on banking human tissues. The biorepository in place today is the result of the combined efforts of the Duke Cancer Institute (DCI) Breast SPORE, DCI Shared Resource for Tissue and Blood Procurement, and the Duke University School of Medicine Research Foundation (DUSOM-RF). The DCI and the School of Medicine Research Foundation (SOMRF) have funded the collection of frozen and fixed tissues, both malignant and benign, under an ?????????????????excess tissue????????????????? protocol that utilizes freshly excised tissue that is available for research after the needs of the pathologic workup are met. This program procures tissues from many anatomic sites including breast. Recently Duke''s Institute of Genome Science & Policy (IGSP), under the direction of Drs. Geoff Ginsburg and Tom Burke, initiated a blood collection program that spans several departments and institutes. The Breast SPORE blood collection program served as the pilot for this much larger effort. The Breast SPORE tissue and blood collection effort utilizes much of the same infrastructure and personnel that are also supported by the DCI, SOMRF, and IGSP.

Proper citation: DCI Tissue and Blood Procurement Shared Resource (RRID:SCR_004116) Copy   

•   Source: SciCrunch Registry

https://reich.hms.harvard.edu/software

Software application that finds skews in ancestry that are potentially associated with disease genes in recently mixed populations like African Americans. It can be downloaded for either UNIX or Linux.

Proper citation: Ancestrymap (RRID:SCR_004353) Copy   

•   Source: SciCrunch Registry

https://www.ctrnet.ca/

The Canadian Tumour Repository Network (CTRNet) is a not-for-profit consortium of leading provincial tumor banks and programs that furthers Canadian health research. CTRNet provides interested researchers with a streamlined process to obtain quality human tissue and human tissue products from member tumor banks. The benefits of working with CTRNet.ca include: * The ability for researchers to search for quality controlled tissue samples from Canada''''s leading tumor banks in one central location and for biobanks to display and make their biospecimens available for research users. * Learning opportunities in tissue handling, research design and relevant technology training and innovations. * Invitation to CTRNet workshops and conferences. * A resource for current news links and discussion forums about cancer research and tumor banking. The vision of CTRNet is to create new opportunities for translational cancer research that will improve cancer outcomes in Canada and beyond. Through the creation and maintenance of an online pan-Canadian network, researchers will gain unprecedented access to a new and comprehensive source of tissue and clinical data. The network is a sustainable resource and operates according to the highest scientific and ethical standards for research to benefit all Canadians. Currently CTRNet has the following member banks: * CBCF Tumor Bank Alberta * Manitoba Tumour Bank * Ontario Tumour Bank * British Columbia Cancer Agency Tumour Tissue Repository (BCCA-TTR) * Le r��seau de recherche en cancer du FRSQ * NCIC Clinical Trials Group

Proper citation: Canadian Tumour Repository Network (RRID:SCR_004192) Copy   

•   Source: SciCrunch Registry

http://www.progeriaresearch.org/cell_tissue_bank.html

The PRF Cell & Tissue Bank provides medical researchers with genetic and biological material from Progeria patients and their families, so that research on Progeria and other age-related diseases can be performed. We''ve been hard at work with the families and their physicians to gather these precious biological materials. As you know, Hutchinson-Gilford Progeria Syndrome is an extremely rare condition. Thus while access to cell lines is essential for studying the biology and genetics of the disorder, there are very few cell lines in existence. Because an integral part of PRF''s mission is to stimulate interest in, and NIH funding opportunities for, Progeria research, there is an increased need for cell lines. The PRF Cell Bank will ensure that need is met! The goals of The PRF Cell & Tissue Bank are to promote: * Sufficient availability of cells for approved research projects * Incentive for new research projects * Study of the biochemical basis for Hutchinson-Gilford Progeria Syndrome * Discoveries leading to new treatments for children with Progeria * Discovery of a cure for Progeria

Proper citation: Progeria Cell and Tissue Bank (RRID:SCR_004194) Copy   

•   Source: SciCrunch Registry

http://biostorage.com/

At BioStorage Technologies, our mission is to provide our clients with world class, biorepository services, exceeding clients����?? expectations of service, value and quality while setting the industry standard for the storage, management & logistics of samples. Offering onsite or outsourced management of sample assets, BioStorage Technologies manages the complete life-cycle of samples. With a team of global sample experts, state-of-the-art temperature-controlled storage facilities, and a real-time web-based sample intelligence and tracking system, the company supports customers in maximizing opportunities, minimizing risk and reducing the cost of sample management. The unique advantages of BioStorage Technologies * Consulting����??Expert consulting on Good Storage Practices, global transport standards, standard operating procedures and business continuity planning to mitigate risk and optimize your resources * Consolidation����??Comprehensive management of the sample lifecycle through consolidation of sample data into one technology system for faster retrieval, more flexible tracking and enhanced security * Control����??Enhanced control of sample asset data within one technology system, ISISS, for faster go/no-go decisions and expansion into future research * Compliance����??Improved chain of custody of your samples and easier audit trail tracking for adherence to quality and regulatory compliance standards in order to support product approvals * Cost-Reduction����??Reduced cost of sample management and increased project ROI through more efficient sample and data management processes, enabling you to refocus resources on your core competencies BioStorage Technologies, Inc. was founded in 2002 and is privately held and headquartered in North America in Indianapolis, Indiana with an additional full-service site in Europe near Frankfurt, Germany.

Proper citation: BioStorage Technologies (RRID:SCR_004302) Copy   

•   Source: SciCrunch Registry

https://www.dtmi.duke.edu/for-researchers/technology-cores/duke-biobank

The Duke Biobank is an institutional resource that combines well-annotated clinical data with a standardized, regulation compliant, cost efficient repository for both fluid and tissue, connected via information systems to a large scale, long-term biobank in Kannapolis, in order to foster breakthroughs in research; while ensuring the strictest adherence to ethical standards and regulations. Our goal is to work with investigators to maintain biorepository collections which are in compliance with all relevant local, regional and national and IRB biobanking standards. Capabilities * Provide expert consultation in planning and design of biobanking programs * Access, process, aliquot, store and distribute a wide array of liquid and tissue biological samples * Maintain informatics capabilities to accurately and efficiently track samples and link to clinical and laboratory assay data * Use the Duke Biobanking Guidelines document (in development) as guidance on scientific, ethical/legal, and operational to ensure quality and standardization of biospecimen collection * Minimize redundancy of infrastructure, as appropriate, across Duke Medicine. Duke University offers both on- and off-campus options for investigators seeking biobanking services. Our biobanking facilities are: * The Center for Human Genetics (CHG). Serves as the primary on-campus biobank for liquid sample storage for Duke Medicine, and as a portal between Duke and the LabCorp Biobank. * Duke Hospital South Tissue Bank. Serves as a sample portal for the Duke Biobank, and as the primary facility for tissue storage for Duke Medicine. ** DCCC Tissue & Blood Procurement ** IGSP Biospecimen Repository * LabCorp Biorepository. Located in Kannapolis, NC, this is the preferred storage center for large-scale, infrequently accessed sample collections

Proper citation: Duke Biobank (RRID:SCR_004304) Copy   

•   Source: SciCrunch Registry

http://www.ucl.ac.uk/cancer/medical-genomics/clinepi

Aims to carry out an integrated (epi)genomic analysis of the NET BioBank established at the Royal Free and UCL Hospitals to identify new biomarkers for translation into diagnostics and therapeutics. The Neuroendocrine Tumour (NET) Unit at the Royal Free Campus of UCL Hospitals has an international reputation for the management of neuroendocrine tumor patients. It currently receives around 10 new referrals per month and has an active patient cohort of over 800 patients. We receive referrals from across the UK as well as from abroad. It is the designated center for NETs within the North London Cancer Network. In order to improve both treatment and outcome in Neuroendocrine Tumors (NETs), better understanding of their biology and the biological pathways involved is imperative (reviewed in (Modlin et al., 2008)). Currently, the use of targeted treatments is limited and management challenging due to the lack of knowledge of the molecular pathogenesis and mechanistic regulation of these tumors (Barakat et al., 2004). Due to the rarity of NETs and difficulty in obtaining fresh tissue and archival samples, very little is known about the (epi)genetic and germline mutations associated with neuroendocrine tumors ����?? which encompass a clinically and genetically heterogeneous group. To date, studies have been small and under-powered. Clinical trials have included small patient numbers and are often non-randomized phase II trials comparing a new therapy against a non-standardized first line treatment. Initially we will undertake genome-wide methylation analysis on our entire cohort of neuroendocrine tumors in order to determine the methylation profiles of differing NET types. This will improve diagnostic accuracy and potentially identify new therapeutic targets and biomarkers. These studies will be performed on high-throughput analysis platforms based on micoarrays and next-generation sequencing. In parallel, we will analyze the mRNA expression profiles of these tumors to enable integrated (epi)genomic analysis of these intriguing tumors.

Proper citation: Neuroendocrine Tumors Biobank (RRID:SCR_004380) Copy   

•   Source: SciCrunch Registry

http://www.uab.edu/medicine/tcbf/sporebb-tpsfsidebar

A biomaterial supply resource which stores and provides ovarian, breast, pancreatic, and cervical tissue samples and fluids to cancer researchers. The UAB Tissue Collection and Banking Facility collects tissue samples for the UAB Ovarian, Breast, Pancreatic, and Cervix SPORE banks. Samples from the former Ovarian SPORE bank are available to UAB Cancer Center members via the Tissue Procurement Shared Facility, and to other researchers via the Cooperative Human Tissue Network.

Proper citation: UAB SPORE Biorepository Banks (RRID:SCR_004419) Copy   

•   Source: SciCrunch Registry

http://htrc.uchicago.edu/biospecimen_bank.php

Biospecimen banking (BSB) involves collecting, processing, storing and distributing of human or animal tissues and body fluids of molecular grade. Human tissues and body fluids are banked in compliance with IRB approved protocols without compromising the diagnostic process and maintaining donor confidentiality (HIPAA compliant). Investigator-driven biobanking initiatives are of paramount importance at the University. The BSB provides investigators with the infrastructure to establish organ-specific biobanks in a centralized location. This arrangement allows for minimal duplication of costs, as well as establishing a working template for all tissue collections. The BSB has grown exponentially, and has a strong team of experienced personnel banking tissues for clinical trials, investigator-driven projects, and future biospecimen-based research. In addition, the BSB now collects and stores saliva, urine, blood, plasma, serum, and derivatives. The BSB is a complex process, requiring multiple interacting systems to ensure the scientific quality of procured tissue, and body fluids, patient confidentiality, adherence to good clinical practices, and regulated disbursement of biospecimens to approved investigators. They are also aware that policies, HIPAA guidelines, and federal and state tissue procurement regulations may change, and will be fully compliant with all new regulations.

Proper citation: University of Chicago Human Tissue Resource Center Biospecimen Banking (RRID:SCR_004418) Copy   

•   Source: SciCrunch Registry

https://healthsciences.ucsd.edu/research/moores/shared-resources/biorepository/Pages/default.aspx

The Biorepository contains plasma, serum, RNA stabilized buffy coat, urine, viable tumor samples, and formalin-fixed paraffin-embedded tumor; all with associated clinical information. These can be provided to investigators with Cancer Sample Banking Committee approval (IRB approval is also required for projects requesting ongoing sample collection or clinical annotation.) Urine and blood-derived specimens are available from a wide variety of cancer cases and cancer-free controls. Tumor sample availability is more limited and predominately from breast and gastrointestinal malignancies. Samples are collected from consented subjects and de-identified clinical information on the subjects is collected over time. Subjects are consented for research germ line genotyping. Access to the clinical annotation is determined based on need as justified in each investigator''s request or protocol. Anonymized samples from the biorepository are available compliant with UCSD HRPP exempt category 4.

Proper citation: UC San Diego Biorepository (RRID:SCR_004256) Copy   

•   Source: SciCrunch Registry

http://sunnybrook.ca/research/?page=sri_core_tbank_home

Sunnybrook Research Institute''s tumour bank provides a mechanism for the optimal collection, storage and distribution of human tissue for investigative purposes. We collect both freshly frozen and formalin-fixed paraffin-embedded tumour and normal samples, retrospectively and prospectively (informed consent and confidential consent is obtained from patients before sample collection). We offer the 1. Distribution of tissue and data to interested investigators after approval from the institutional research ethics board and 2. Collaboration with various research investigators. Our mandate is to design, implement and manage the structures and processes to ensure the timely provision of tissue samples and associated data. We are currently building bank on four disease sites: breast, prostate, colorectal, gynecological. We are also creating and maintaining a database with a tissue tracking and inventory system, using TissueMetrix software.

Proper citation: Sunnybrook Tumour Bank (RRID:SCR_004138) Copy   

•   Source: SciCrunch Registry

http://www.lerner.ccf.org/gmi/gmb/

A biorepository is a place where investigators can deposit and store biological material, in this case samples derived from patients. Moreover, the Genomic Medicine Institute (GMI) takes this basic concept and elevates it to make the Genomic Medicine Biorepository (GMB) a full-service processing and banking laboratory that serves as the foundation for evidence-based research for the GMI, the Cleveland Clinic, and our collaborators. The process relies on a team of multi-disciplinary professionals coordinating their efforts in order to streamline medical research. This begins with dedicated physicians and genetic counselors identifying individuals with specific medical conditions indicating the possibility of genetic involvement. Once identified, biological material (e.g. blood, tissue, or saliva) is collected under the care of the patient''s doctor or by our clinicians and sent to the GMB. Once in the lab, the patient and their samples are assigned a unique identifier (to protect the patient''s personal information) and logged into a central database. This unique identifier accompanies all samples processed and banked for that individual. The specimens are then processed into research-relevant samples using proven laboratory techniques and state-of-the-art quality control practices. These samples include the isolation of DNA and RNA from white blood cells for genetic studies; collection of plasma for proteomic studies; and initiated immortalized cell lines from lymphocytes for in-vitro studies and biochemical research. These cell lines are able to be indefinitely stored in cryogenic suspension and are invaluable as a renewable resource for genetic and biochemical research. The GMB also processes genetic material from various tissues (both fresh and archived). Charis Eng, MD, PhD, Chair and Director of the GMI, has been the faculty oversight person of a human biorepository for the last eight years. Since then, our biorepository has received, cataloged, processed, and banked, in excess of 25,000 specimens. These samples are of numerous tissue types from patients and their family members located all over the world. Our biorepository has managed samples that have resulted in more than 150 original peer reviewed articles and greater than $25 million total direct costs in extramural funding over the last four years alone.

Proper citation: Cleveland Clinic Genomic Medicine Biorepository (RRID:SCR_004136) Copy   

•   Source: SciCrunch Registry

https://www.bips-institut.de/en/research/biobank.html

Biobank that contains more than 50,000 blood, urine and saliva samples as well as tissue materials from epidemiological field studies. The samples and DNA collected in various studies are increasingly being used for the investigation of genetic, environmental and life-style associated factors in the etiology and prognosis of cancer and other chronic diseases such as obesity, diabetes and metabolic syndrome.

Proper citation: Leibniz Institute for Prevention Research and Epidemiology Biobank (RRID:SCR_004094) Copy   

•   Source: SciCrunch Registry